Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Gilteritinib in the management of acute myeloid leukemia: Current evidence and future directions.

Leukemia research - 1 Mar 2022

Nuhoğlu Kantarcı Eda, Eşkazan Ahmet Emre

Abstract excerpt

Acute myeloid leukemia (AML) is defined as a highly progressive heterogeneous hematologic malignancy characterized by loss of differentiation with uncontrolled proliferation of progenitor cells. 5-year overall survival rates are as low as 5-10% in adults above 60 years. Until recently, available treatment options for AML had remained mainly unchanged. Along with the development and usage of new generation drugs,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aniline Compounds
Share to fms-Like Tyrosine Kinase 3
Share to Leukemia, Myeloid, Acute

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Pyrazines

Source

Identifiers

PMID: 35176548
DOI: 10.1016/j.leukres.2022.106808

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gilteritinib in the management of acute myeloid leukemia: Current evidence and future directions.PMID 35176548Read ↗

Gilteritinib: An FMS-like tyrosine kinase 3/AXL tyrosine kinase inhibitor for the treatment of relapsed or refractory acute myeloid leukemia patients.Semantic proximity Read ↗

Advances in clinical studies of FLT3 inhibitors in acute myeloid leukemia.Semantic proximity Read ↗

A review of FLT3 inhibitors in acute myeloid leukemia.Semantic proximity Read ↗

Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a FLT3 mutation.Semantic proximity Read ↗

Clinical Efficacies of FLT3 Inhibitors in Patients with Acute Myeloid Leukemia.Semantic proximity Read ↗

Enhancing Therapeutic Efficacy of FLT3 Inhibitors with Combination Therapy for Treatment of Acute Myeloid Leukemia.Semantic proximity Read ↗

Gilteritinib: potent targeting of FLT3 mutations in AML.Semantic proximity Read ↗

Gilteritinib: The Story of a Proceeding Success into Hard-to-Treat FLT3 Mutated AML PatientsSemantic proximity Read ↗

The European Medicines Agency Review of Gilteritinib (Xospata) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an FLT3 Mutation.Semantic proximity Read ↗

Therapeutic Targeting of FLT3 in Acute Myeloid Leukemia: Current Status and Novel ApproachesSemantic proximity Read ↗

[Efficacy and safety of gilteritinib combined with chemotherapy in newly diagnosed FLT3-mutated acute myeloid leukemia].Semantic proximity Read ↗

FMS-Like Tyrosine Kinase 3 Inhibitors for the Treatment of Acute Myeloid Leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.